# Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer

> **NCT06801236** · PHASE1 · RECRUITING · sponsor: **Acerand Therapeutics (Hong Kong) Limited** · enrollment: 67 (estimated)

## Conditions studied

- Prostate Cancer (Adenocarcinoma)
- mCRPC (Metastatic Castration-resistant Prostate Cancer)

## Interventions

- **DRUG:** ACE-232 tablets

## Key facts

- **NCT ID:** NCT06801236
- **Lead sponsor:** Acerand Therapeutics (Hong Kong) Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-12
- **Primary completion:** 2028-03-01
- **Final completion:** 2028-08-01
- **Target enrollment:** 67 (ESTIMATED)
- **Last updated:** 2026-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06801236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06801236, "Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06801236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*